FUNDAMENTALS · Fundamentals · CN Healthcare

Hansoh Pharmaceutical Group (3692) Fundamentals 2026 — P/E 30.5x, Revenue Analysis | SniperIQ

Hansoh Pharmaceutical Group (3692) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of HK

99.2B, trading at HK
2.86 on the HKSE. This SniperIQ fundamentals page covers Hansoh Pharmaceutical Group's valuation (P/E 30.5x, P/B 4.8x), profitability (net margin 37.0%), revenue (¥15.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
99.2B
P/E (TTM)30.5x
Net Margin37.0%
Revenue (FY25)¥15.0B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Hansoh Pharmaceutical Group's market cap?

Hansoh Pharmaceutical Group (3692) has a market capitalization of approximately HK

99.2B, trading at HK
2.86 on the HKSE. Market cap moves with the live share price.

What is Hansoh Pharmaceutical Group's P/E ratio?

Hansoh Pharmaceutical Group's trailing twelve-month P/E ratio is 30.5x, with a price-to-book (P/B) of 4.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Hansoh Pharmaceutical Group?

Hansoh Pharmaceutical Group runs a net profit margin of 37.0%, a gross margin of 89.9%, and an operating margin of 36.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Hansoh Pharmaceutical Group generate?

Hansoh Pharmaceutical Group reported revenue of ¥15.0B for fiscal year 2025, with net income of ¥5.6B and earnings per share (EPS) of 0.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Hansoh Pharmaceutical Group pay a dividend?

Hansoh Pharmaceutical Group offers a trailing dividend yield of about 1.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Hansoh Pharmaceutical Group financially healthy?

Hansoh Pharmaceutical Group carries a debt-to-equity ratio of 0.00x and a current ratio of 8.09x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Hansoh Pharmaceutical Group a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hansoh Pharmaceutical Group (3692) the key facts are: market cap HK

99.2B, P/E 30.5x, revenue ¥15.0B, 52-week range 28.06-44.22. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Hansoh Pharmaceutical Group's full fundamentals live

Get Hansoh Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: EASY BIO (353810) fundamentals · Amgen (AMGN) fundamentals · Eris Lifesciences (ERIS) fundamentals · Vieworks (100120) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons